July 10, 2012 -- The Team of TheBioTechPanel Inc. is proud to announce the addition of ImmuPharma’s interview to its´ Internet-TV site, TheBioTechPanel-TV.com.
About ImmuPharma Plc.:
ImmuPharma plc. (LSE:IMM) is a drug discovery and development group in London, U.K. with operations in its subsidiaries in Mulhouse, France and Basle, Switzerland. The company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders . Each would represent a significant breakthrough in its field. The company also has a strong proprietary and collaborative drug development pipeline. ImmuPharma was founded and is led by a management team with extensive experience in the international pharma industry, business and finance. ImmuPharma plc is publicly listed in London and its shares trade under the symbol IMM (LSE: IMM or for Bloomberg IMM: LN). http://www.immupharma.org/
The site’s goal is to boost awareness for Life Science Companies and their products, services, licensing deals, funding plans, trials, news, stock quotations etc., by approaching a broad target group of retail and institutional investors in Europe and globally.
How does it work? Very simple: You just send us a video presentation of your choice, and we will be pleased to load it onto our Internet-TV site. Then, we market the new video via different news channels, thereby raising attention for your Company. Also, with every new announcement for someone else’s video, your Company will additionally be in the focus of investors.
For whom is this offer interesting? For every Life Science Company which is interested in boosting awareness. The monthly costs are affordable (especially when compared to expensive and not as effective roadshows); moreover, it is permanent and can be updated with new video presentations on a monthly basis.
Any questions? Please contact us at email@example.com